A start‑up develops a tomato with a small gene edit introduced by CRISPR without inserting foreign DNA. Analyze regulatory implications under current U.S. frameworks and identify the most likely oversight gap.

• A. Products with CRISPR edits are required under current rules to be labeled identically to organic products, including the USDA organic seal, because they are derived from nontraditional breeding methods.
• B. Because CRISPR edits may not involve recombinant DNA, they can fall outside frameworks designed for transgenic organisms, creating regulatory ambiguity: USDA bioengineered rules focused on recombinant DNA may not clearly apply, potentially leaving labeling and oversight uncertain until agencies update guidance.
• C. All new gene edits are uniformly regulated by the EPA as pesticides, because edits are reclassified as environmental control agents regardless of method used.
• D. CRISPR edits are automatically considered illegal under USDA law, and no oversight is possible until the company obtains a special congressional waiver.

Answer: (B)